1. Home
  2. HTH vs AKRO Comparison

HTH vs AKRO Comparison

Compare HTH & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hilltop Holdings Inc.

HTH

Hilltop Holdings Inc.

HOLD

Current Price

$34.51

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.54

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTH
AKRO
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
4.5B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
HTH
AKRO
Price
$34.51
$54.54
Analyst Decision
Hold
Buy
Analyst Count
2
10
Target Price
$34.00
$73.56
AVG Volume (30 Days)
365.5K
1.7M
Earning Date
10-23-2025
11-07-2025
Dividend Yield
2.09%
N/A
EPS Growth
53.28
N/A
EPS
2.50
N/A
Revenue
$1,259,399,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.64
N/A
P/E Ratio
$13.76
N/A
Revenue Growth
7.66
N/A
52 Week Low
$26.67
$21.34
52 Week High
$36.14
$58.40

Technical Indicators

Market Signals
Indicator
HTH
AKRO
Relative Strength Index (RSI) 55.34 66.54
Support Level $34.32 $54.22
Resistance Level $35.35 $54.70
Average True Range (ATR) 0.81 0.14
MACD 0.09 -0.11
Stochastic Oscillator 70.13 64.18

Price Performance

Historical Comparison
HTH
AKRO

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: